



## Results of 2026 Extraordinary General Meeting

**MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 May 2026:** [Alterity Therapeutics](#) (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that in accordance with ASX Listing rule 3.13.2 and Section 251AA of the *Corporations Act 2001* (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Alterity Therapeutics Limited at its Extraordinary General Meeting held on 29 May 2026.

### **About Alterity Therapeutics Limited**

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at <https://alteritytx.com>.

### **Authorisation & Additional information**

This announcement was authorised by the Board of Alterity Therapeutics Limited.

### **Contacts:**

#### **Investors:**

Elyse Shapiro

[ir@alteritytx.com](mailto:ir@alteritytx.com)

Remy Bernarda

Investor Relations Advisory Solutions

[ir@alteritytx.com](mailto:ir@alteritytx.com)

+1 (415) 203-6386

## Media

Casey McDonald

Tiberend Strategic Advisors, Inc.

[cmcdonald@tiberend.com](mailto:cmcdonald@tiberend.com)

+1 (646) 577-8520

## Forward Looking Statements

*This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.*

*Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the Company's filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company's drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company's patent rights and the uncertainty of the Company freedom to operate.*

*Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.*

# Disclosure of Proxy Votes

Alteryx Therapeutics Limited

General Meeting

Friday, 29 May 2026



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ELECTION OF DIRECTOR – MR JULIAN BABARCZY	P	3,595,476,356	3,107,696,597 86.43%	446,154,929 12.41%	1,845,314	41,624,830 1.16%	3,160,365,713 87.63%	446,154,929 12.37%	1,845,314	Carried
2 ELECTION OF DIRECTOR – MS ANN CUNNINGHAM	P	3,595,463,756	3,569,356,223 99.27%	20,486,203 0.57%	1,857,914	5,621,330 0.16%	3,586,021,839 99.43%	20,486,203 0.57%	1,857,914	Carried
3 CONSOLIDATION OF CAPITAL	P	3,589,130,356	3,502,140,174 97.58%	81,297,424 2.27%	8,191,314	5,692,758 0.16%	3,507,832,932 97.44%	92,341,710 2.56%	8,191,314	Carried
4 APPROVAL TO ISSUE OPTIONS TO DIRECTOR – MR JULIAN BABARCZY	P	3,593,598,277	2,969,540,026 82.63%	553,365,493 15.40%	3,723,393	70,692,758 1.97%	3,040,232,784 84.60%	553,365,493 15.40%	14,767,679	Carried
5 APPROVAL TO ISSUE OPTIONS TO MONTOYA PTY LTD ATF BUTTERCUP TRUST	P	3,593,010,877	3,379,430,045 94.06%	207,888,074 5.79%	4,310,793	5,692,758 0.16%	3,385,122,803 94.21%	207,888,074 5.79%	15,355,079	Carried
6 AMENDMENT TO CONSTITUTION	P	3,590,419,791	3,369,030,153 93.83%	215,264,808 6.00%	6,901,879	6,124,830 0.17%	3,386,199,269 94.02%	215,264,808 5.98%	6,901,879	Carried
7 APPROVAL TO ISSUE SECURITIES UNDER AN INCENTIVE PLAN	P	3,559,461,277	3,427,086,943 96.28%	126,749,504 3.56%	37,860,393	5,624,830 0.16%	3,443,756,059 96.45%	126,749,504 3.55%	37,860,393	Carried

